KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $1.9 billion.

  • Vertex Pharmaceuticals' Operating Expenses rose 1417.01% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 billion, marking a year-over-year decrease of 2905.88%. This contributed to the annual value of $11.3 billion for FY2024, which is 8639.44% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Operating Expenses stood at $1.9 billion for Q3 2025, which was up 1417.01% from $1.8 billion recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Operating Expenses peaked at $6.2 billion during Q2 2024, and registered a low of $836.5 million during Q1 2021.
  • Its 5-year average for Operating Expenses is $1.7 billion, with a median of $1.5 billion in 2023.
  • In the last 5 years, Vertex Pharmaceuticals' Operating Expenses surged by 31998.23% in 2024 and then tumbled by 7055.99% in 2025.
  • Vertex Pharmaceuticals' Operating Expenses (Quarter) stood at $1.2 billion in 2021, then grew by 6.22% to $1.3 billion in 2022, then increased by 20.49% to $1.5 billion in 2023, then rose by 23.33% to $1.9 billion in 2024, then rose by 0.22% to $1.9 billion in 2025.
  • Its Operating Expenses stands at $1.9 billion for Q3 2025, versus $1.8 billion for Q2 2025 and $2.1 billion for Q1 2025.